Located in the south of France and spin-off of PMB-ALCEN, THERYQ is an innovative medical technology company specializing in the design and production of radiotherapy machines incorporating linear accelerators. The company masters and provides essential expertise on project management, R&D, industrialization and manufacturing. THERYQ is part of ALCEN’s Healthcare branch.
THERYQ aims to introduce a revolutionary technology in 2 steps:
- FLASHKNiFE, a product already developed to treat tumors up to 4 cm-deep with on-going clinical trials
- FLASHDEEP, to develop and validate the first FLASH device for external radiotherapy of all deep-seated tumors
With this new technology, THERYQ will:
- Significantly increase patients’ opportunities to be cured of their cancer
- Decrease treatment cost
- Offer clinicians new solutions to better treat cancer
THERYQ is a spin-off of the company PMB, which led the pioneering projects on FLASH since 2013 and has a long-standing collaboration with several prominent institutions around the world. A transfer by PMB to THERYQ of the complete branch of activity dedicated to its radiotherapy business was done in 2022.